Arisha Patel

651 total citations · 1 hit paper
9 papers, 404 citations indexed

About

Arisha Patel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Arisha Patel has authored 9 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in Arisha Patel's work include Gastric Cancer Management and Outcomes (3 papers), Hemoglobinopathies and Related Disorders (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Arisha Patel is often cited by papers focused on Gastric Cancer Management and Outcomes (3 papers), Hemoglobinopathies and Related Disorders (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Arisha Patel collaborates with scholars based in United States, United Kingdom and Switzerland. Arisha Patel's co-authors include Funda Meric‐Bernstam, John D. Hainsworth, Howard A. Burris, Razelle Kurzrock, Jonathan Levy, Charles Swanton, Claire F. Friedman, Christopher J. Sweeney, Katja Schulze and David R. Spigel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Arisha Patel

9 papers receiving 398 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

2021 251 citations Milind Javle, Mitesh J. Borad et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Arisha Patel

Since Specialization

Citations

This map shows the geographic impact of Arisha Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arisha Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arisha Patel more than expected).

Fields of papers citing papers by Arisha Patel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arisha Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arisha Patel. The network helps show where Arisha Patel may publish in the future.

Co-authorship network of co-authors of Arisha Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Arisha Patel. A scholar is included among the top collaborators of Arisha Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arisha Patel. Arisha Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm 2022 ·JCO Clinical Cancer Informatics ·(unknown), (unknown), (unknown), T. Asakawa, (unknown), (unknown), Irmarie Reyes‐Rivera, Arisha Patel, Yoshiaki Nakamura	9
2	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study 2021 ·Cancer Discovery ·Claire F. Friedman, John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney, Funda Meric‐Bernstam, Yong Wang, Jonathan Levy, Jessica M. Grindheim, David S. Shames, Katja Schulze, Arisha Patel, Charles Swanton	56
3	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study breakdown → 2021 ·The Lancet Oncology ·Milind Javle, Mitesh J. Borad, Nilofer S. Azad, Razelle Kurzrock, Ghassan K. Abou‐Alfa, Ben George, John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Christopher J. Sweeney, Claire F. Friedman, Ron Bose, David R. Spigel, Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard A. Burris	251
4	MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. 2021 ·Journal of Clinical Oncology ·Funda Meric‐Bernstam, John D. Hainsworth, Ron Bose, Howard A. Burris, Claire F. Friedman, Razelle Kurzrock, Charles Swanton, Yong Wang, Jonathan Levy, Katja Schulze, (unknown), Arisha Patel, Christopher J. Sweeney	32
5	Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort 2021 ·Cancer Research ·John D. Hainsworth, Claire F. Friedman, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney, Funda Meric‐Bernstam, Yong Wang, Jonathan Levy, David S. Shames, Katja Schulze, Arisha Patel, Charles Swanton	2
6	Machine‐learning algorithms for predicting hospital re‐admissions in sickle cell disease 2020 ·British Journal of Haematology ·Arisha Patel, (unknown), Andrew A. Li, Jeremy C. Weiss, Mehdi Nouraie, Sridhar Tayur, Enrico M. Novelli	8
7	Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission 2020 ·Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ·Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing‐Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen Dorritie, Alison R. Sehgal, James M. Rossetti, Melissa Saul, Daniel P. Normolle, Konstantinos Lontos, Michael Boyiadzis	7
8	Machine Learning Algorithms in Predicting Hospital Readmissions in Sickle Cell Disease 2019 ·Blood ·Arisha Patel, (unknown), (unknown), Jeremy C. Weiss, Mehdi Nouraie, (unknown), Enrico M. Novelli	3
9	The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T‐cell lymphoma, nasal type, in the United States 2017 ·Cancer ·John A. Vargo, Arisha Patel, Scott Glaser, G.K. Balasubramani, Rafic Farah, Stanley M. Marks, Sushil Beriwal	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact